Fremazenumab
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1590/2022-SML | 05. 10. 2022 | Teva Pharmaceuticals CR, s.r.o. | 31 748 015,20 | 28 861 832,00 | 31 748 015,20 | 28 861 832,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva zadavatele_Fremazenumab.pdf | Písemná zpráva zadavatele | 07. 10. 2022 12:47 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Teva Pharmaceuticals CR, s.r.o. | Praha | 31 748 015,20 | 28 861 832,00 | CZK |
Price Actually Paid in Each Year of Performance
| 1590/2022-SML | 2023 | 7 248 049,59 | 6 589 135,99 |
| 1590/2022-SML | 2022 | 676 209,28 | 614 735,71 |